IP Library Granted Patent US 11,529,511
Granted Patent B2
US 11,529,511 · App. 16/502,282 · Granted Dec 20, 2022

Using alternating electric fields to increase cell membrane permeability

Inventors: Edwin Chang (Menlo Park, CA); Chirag B. Patel (Palo Alto, CA); Sanjiv S. Gambhir (Portola Valley, CA); Tali Voloshin-Sela (Kibbutz Gvat, IL); Yaara Porat (Kibbutz Galed, IL); Moshe Giladi (Moshav Herut, IL)
Assignees: The Board of Trustees of the Leland Stanford Junior University; Novocure GmbH
A61N1/327A61F7/007A61K41/0061A61N1/025A61N1/36002A61N1/3603A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,529,511
App. No.
16/502,282
Granted
Dec 20, 2022
Kind
B2
Abstract

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

Claims (21)

1. A method for attacking cancer cells, the method comprising:

applying a first alternating electric field at a first frequency to the cancer cells for a first period of time, wherein application of the first alternating electric field at the first frequency to the cancer cells for the first period of time increases permeability of cell membranes of the cancer cells;

introducing a substance to the cancer cells, wherein the increased permeability of the cell membranes enables the substance to cross the cell membranes; and

applying a second alternating electric field at a second frequency to the cancer cells for a second period of time, wherein the second frequency is different from the first frequency, and wherein the second alternating electric field at the second frequency reduces viability of the cancer cells.

2. The method of claim 1 , wherein the cancer cells comprise glioblastoma cells, the first frequency is between 250 kHz and 350 kHz, and the second frequency is between 150 kHz and 250 kHz.

3. The method of claim 1 , wherein the cancer cells comprise uterine sarcoma cells, the first frequency is between 125 kHz and 175 kHz, and the second frequency is between 75 kHz and 125 kHz.

4. The method of claim 1 , wherein the cancer cells comprise breast adenocarcinoma cells, the first frequency is between 75 kHz and 175 kHz, and the second frequency is between 100 kHz and 300 kHz.

5. The method of claim 1 , wherein the step of introducing the substance begins at a given time, and wherein the step of applying the first alternating electric field ends at least 12 hours after the given time.

6. The method of claim 1 , wherein the first alternating electric field has a field strength of at least 1 V/cm RMS.

7. The method of claim 1 , wherein the substance has a molecular weight of at least 1.2 kDa.

8. The method of claim 1 , wherein the substance has a molecular weight of at least 4 kDa.

9. The method of claim 1 , wherein the substance has a molecular weight of at least 20 kDa.

10. A method for treating a tumor in a subject's body and delivering a substance across cell membranes in the subject's body, the method comprising:

applying a first alternating electric field at a first frequency to the subject's body for a first period of time, wherein application of the first alternating electric field at the first frequency to the subject's body for the first period of time increases permeability of the cell membranes in the subject's body;

administering the substance to the subject, wherein the increased permeability of the cell membranes enables the substance to cross the cell membranes; and

applying a second alternating electric field at a second frequency to the subject's body for a second period of time that is at least one week long, wherein the second frequency is different from the first frequency, and wherein the second alternating electric field at the second frequency inhibits growth of the tumor.

11. The method of claim 10 , wherein the tumor comprises a glioblastoma in the subject's brain, the first frequency is between 250 kHz and 350 kHz, and the second frequency is between 150 kHz and 250 kHz.

12. The method of claim 10 , wherein the second period of time comprises a plurality of non-contiguous intervals of time during which the second alternating electric field at the second frequency is applied to the subject's body, wherein the plurality of non-contiguous intervals of time collectively add up to at least one week.

13. The method of claim 10 , wherein the step of administering the substance begins at a given time, and wherein the step of applying the first alternating electric field ends at least 12 hours after the given time.

14. The method of claim 13 , wherein the step of applying the first alternating electric field begins at least one hour before the given time.

15. The method of claim 10 , wherein the substance has a molecular weight of at least 1.2 kDa.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2021
From: CHANG, EDWIN; PATEL, CHIRAG B.; GAMBHIR, SANJIV S.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 055795/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2021
From: VOLOSHIN-SELA, TALI; PORAT, YAARA; GILADI, MOSHE
To: NOVOCURE GMBH
Reel/Frame 055796/0194 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →